Basecamp Wealth Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Basecamp Wealth Advisors's BMY Position: Q3 2026 in Review
Basecamp Wealth Advisors reduced its Bristol-Myers Squibb (BMY) stake by 58% in Q3 2026, selling an estimated $219K and leaving 2,498 shares worth $156K. The position accounts for 0.04% of the portfolio, ranked #237.
Basecamp Wealth Advisors first reported a position in BMY in Q4 2025 and has held it in 4 quarters since. The position peaked at $392K in Q1 2026. 2,568 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Basecamp Wealth Advisors held 2,498 shares of Bristol-Myers Squibb worth $156K as of Q3 2026.
- Basecamp Wealth Advisors sold 3,464 Bristol-Myers Squibb shares in Q3 2026, an estimated $219K.
- Bristol-Myers Squibb made up 0.04% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #237 holding.
- Basecamp Wealth Advisors first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 4 quarters since.
- Basecamp Wealth Advisors's Bristol-Myers Squibb position peaked at $392K in Q1 2026.
- 2,568 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.